
|Articles|February 15, 2004
FDA multicenter trial confirms CK safety, efficacy for hyperopia
Anaheim, CA-Conductive keratoplasty (CK), a thermokeratoplasty technique used to reshape the cornea, appears to be a safe and effective approach for treating low to moderate hyperopia with little or no induced astigmatism, according to Marguerite B. McDonald, MD, medical monitor of the FDA multicenter trial.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Iolyx Therapeutics and Laboratoires Théa enter into agreement over ILYX-002 for the treatment of OSD
2
Avisi Technologies treats first patient in SAPPHIRE trial for glaucoma
3
PainReform launches development plan for OcuRing-K, readies phase 2 trial
4
First patient treated in ViaLase’s IDE trial
5















































.png)


